


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT SHARE INCREASING PLAN BY THE CHAIRMAN OF THE BOARD

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Insilico Medicine**”) on a voluntary basis.

Based on the confidence in the future development prospects of the Company and the recognition of the long-term investment value of the Company, Mr. Aleksandrs Zavoronkovs, Ph.D. (“**Mr. Zavoronkovs**”), chairman of the board (the “**Board**”) of directors (the “**Director(s)**”), executive Director, chief executive officer and chief business officer of the Company, subject to compliance with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited and other applicable laws and regulations, initiates the plan for purchase of additional shares of the Company in the open market using his personal funds (the “**Share Increasing Plan**”). The share purchases will take place during September 2026, with an estimated total amount up to HKD16 million. Previously, Mr. Zavoronkovs has also invested in the Company’s Series D financing in 2022.

Based on the information available to the Company and to the best knowledge and belief of the Directors, the Company will continue to maintain a sufficient public float of the shares in issue, if the Share Increasing Plan is implemented.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, September 4, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive Directors; Mr. Chuen Yan Leung, Ph.D. as a non-executive Director; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive Directors.